Shenzhen Bioeasy Biotechnology Co (300942) Fair Value & Analysis
Healthcare · CN · Market cap 2.5B CNY
Fair value as of: Jun 24, 2026
Analysis
Shenzhen Bioeasy Biotechnology Co (300942) currently trades at ¥6.20, while our model-based Fair Value estimate is ¥0.7500 — implying the stock looks roughly 87.9% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
About the company
Shenzhen Bioeasy Biotechnology Co., Ltd., together with its subsidiaries, provides rapid food testing reagents and instruments in China and internationally. The company offers test kits, including veterinary, melamine, mycotoxin, pesticide, adulteration, ATP, vitamin, and others; equipment, such as incubator, reader, suitcase lab, automatic pressers, and others; and materials comprising pretreatment column, certified reference, and quality control. It also provides specialized solutions, which include multi-mode precision detection, project plan for specialized equipment, AI-powered fully automated grain comprehensive testing workstation, digital food safety automatic detection, rapid testing laboratory, smart supervision, and comprehensive solution for rapid testing. In addition, the company offers software platforms, such as smart grain depot, traceability, orchard, datian, tea garden, and park project, as well as digital village project and agricultural and rural data projects. I…
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Shenzhen Bioeasy Biotechnology Co (300942) undervalued?
What is the fair value of 300942?
What is the quality score of 300942?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.